| Identification | Back Directory | [Name]
Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-2-[[5-(4-hydroxy-1-piperazinyl)-2-pyridinyl]amino]-5-methyl- | [CAS]
2231085-26-8 | [Synonyms]
N-Hydroxy Palbociclib
6-acetyl-8-cyclopentyl-2-((5-(4-hydroxypiperazin-1-yl)pyridin-2-yl)amino)-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one
Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-2-[[5-(4-hydroxy-1-piperazinyl)-2-pyridinyl]amino]-5-methyl- | [Molecular Formula]
C24H29N7O3 | [MOL File]
2231085-26-8.mol | [Molecular Weight]
463.53 |
| Chemical Properties | Back Directory | [Melting point ]
>200°C (dec.) | [Boiling point ]
742.2±70.0 °C(Predicted) | [density ]
1.393±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
12.88±0.20(Predicted) | [color ]
Light Yellow to Yellow |
| Hazard Information | Back Directory | [Uses]
N-Hydroxy Palbociclib is an impurity of Palbociclib (P139900), an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. |
|
|